{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:00:19Z","timestamp":1768824019112,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"DOI":"10.7759\/cureus.84904","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:50:22Z","timestamp":1748364622000},"source":"Crossref","is-referenced-by-count":1,"title":["Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences"],"prefix":"10.7759","author":[{"given":"Suhas","family":"Kataveni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raga Priya","family":"Gourishetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti M","family":"Mundada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moksha Prasoona","family":"Avvaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay S","family":"Kollipara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Pranay","family":"Gottimukkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2755","article-title":"Beta(2) -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men","volume":"12","author":"Jessen S","year":"2020","unstructured":"Jessen S, Solheim SA, Jacobson GA, Eibye K, Bangsbo J, Nordsborg NB, Hostrup M. Beta(2) -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. Drug Test Anal. 2020, 12:610-8. 10.1002\/dta.2755","journal-title":"Drug Test Anal"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkz058","article-title":"Complete post-mortem investigations in a death involving clenbuterol after long-term abuse","volume":"43","author":"Kintz P","year":"2019","unstructured":"Kintz P, Gheddar L, Ameline A, Dumestre-Toulet V, Verschoore M, Comte J, Raul JS. Complete post-mortem investigations in a death involving clenbuterol after long-term abuse. J Anal Toxicol. 2019, 43:660-5. 10.1093\/jat\/bkz058","journal-title":"J Anal Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12991","article-title":"\u0392-2 agonists as misusing drugs? Assessment of both clenbuterol- and salbutamol-related European Medicines Agency pharmacovigilance database reports","volume":"123","author":"Milano G","year":"2018","unstructured":"Milano G, Chiappini S, Mattioli F, Martelli A, Schifano F. \u0392-2 agonists as misusing drugs? Assessment of both clenbuterol- and salbutamol-related European Medicines Agency pharmacovigilance database reports. Basic Clin Pharmacol Toxicol. 2018, 123:182-7. 10.1111\/bcpt.12991","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-819955","article-title":"Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study","volume":"25","author":"Geyer H","year":"2004","unstructured":"Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Sch\u00e4nzer W. Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int J Sports Med. 2004, 25:124-9. 10.1055\/s-2004-819955","journal-title":"Int J Sports Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.3337","article-title":"Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings","volume":"1","author":"Tucker J","year":"2018","unstructured":"Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open. 2018, 1:e183337. 10.1001\/jamanetworkopen.2018.3337","journal-title":"JAMA Netw Open"},{"key":"ref6","unstructured":"Tainted weight loss products. (2024). Accessed. May 12, 2025: https:\/\/www.fda.gov\/drugs\/medication-health-fraud\/tainted-weight-loss-products."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2014-093526","article-title":"Anabolic agents: recent strategies for their detection and protection from inadvertent doping","volume":"48","author":"Geyer H","year":"2014","unstructured":"Geyer H, Sch\u00e4nzer W, Thevis M. Anabolic agents: recent strategies for their detection and protection from inadvertent doping. Br J Sports Med. 2014, 48:820-6. 10.1136\/bjsports-2014-093526","journal-title":"Br J Sports Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/foods9081012","article-title":"Dietary supplement and food contaminations and their implications for doping controls","volume":"9","author":"Walpurgis K","year":"2020","unstructured":"Walpurgis K, Thomas A, Geyer H, Mareck U, Thevis M. Dietary supplement and food contaminations and their implications for doping controls. Foods. 2020, 9:1012. 10.3390\/foods9081012","journal-title":"Foods"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2021.07.023","article-title":"Pharmacologic approaches to prevent skeletal muscle atrophy after spinal cord injury","volume":"60","author":"Otzel DM","year":"2021","unstructured":"Otzel DM, Kok HJ, Graham ZA, Barton ER, Yarrow JF. Pharmacologic approaches to prevent skeletal muscle atrophy after spinal cord injury. Curr Opin Pharmacol. 2021, 60:193-9. 10.1016\/j.coph.2021.07.023","journal-title":"Curr Opin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5694\/mja13.10982","article-title":"Clenbuterol toxicity: a NSW poisons information centre experience","volume":"200","author":"Brett J","year":"2014","unstructured":"Brett J, Dawson AH, Brown JA. Clenbuterol toxicity: a NSW poisons information centre experience. Med J Aust. 2014, 200:219-21. 10.5694\/mja13.10982","journal-title":"Med J Aust"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1185\/03007998509109643","article-title":"Effect of clenbuterol on peripheral airway obstruction in bronchial asthma","volume":"9","author":"Hida W","year":"1985","unstructured":"Hida W, Sakurai M, Ichinose M, et al.. Effect of clenbuterol on peripheral airway obstruction in bronchial asthma. Curr Med Res Opin. 1985, 9:616-25. 10.1185\/03007998509109643","journal-title":"Curr Med Res Opin"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.05.010","article-title":"Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action","volume":"99","author":"Dutt V","year":"2015","unstructured":"Dutt V, Gupta S, Dabur R, Injeti E, Mittal A. Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action. Pharmacol Res. 2015, 99:86-100. 10.1016\/j.phrs.2015.05.010","journal-title":"Pharmacol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.8.385","article-title":"Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit","volume":"8","author":"Yamamoto I","year":"1985","unstructured":"Yamamoto I, Iwata K, Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. J Pharmacobiodyn. 1985, 8:385-91. 10.1248\/bpb1978.8.385","journal-title":"J Pharmacobiodyn"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1992.263.1.E50","article-title":"Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation","volume":"263","author":"Choo JJ","year":"1992","unstructured":"Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. Am J Physiol. 1992, 263:E50-6. 10.1152\/ajpendo.1992.263.1.E50","journal-title":"Am J Physiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb11211.x","article-title":"Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol","volume":"90","author":"Rothwell NJ","year":"1987","unstructured":"Rothwell NJ, Stock MJ, Sudera DK. Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol. Br J Pharmacol. 1987, 90:601-7. 10.1111\/j.1476-5381.1987.tb11211.x","journal-title":"Br J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/9781118105955","article-title":"Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants","author":"Barceloux DG","year":"2012","unstructured":"Barceloux DG. Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons, Inc., Hoboken, NJ; 2012. 10.1002\/9781118105955"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1249\/00005768-199508000-00003","article-title":"Clenbuterol: a substitute for anabolic steroids?","volume":"27","author":"Prather ID","year":"1995","unstructured":"Prather ID, Brown DE, North P, Wilson JR. Clenbuterol: a substitute for anabolic steroids?. Med Sci Sports Exerc. 1995, 27:1118-21.","journal-title":"Med Sci Sports Exerc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-3928(01)00032-4","article-title":"Doping in sports: cardiovascular effects","volume":"50","author":"Gauthier J","year":"2001","unstructured":"Gauthier J. Doping in sports: cardiovascular effects. Ann Cardiol Ang\u00e9iologie. 2001, 50:293-8. 10.1016\/S0003-3928(01)00032-4","journal-title":"Ann Cardiol Ang\u00e9iologie"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2013.772083","article-title":"A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding","volume":"34","author":"Spiller HA","year":"2013","unstructured":"Spiller HA, James KJ, Scholzen S, Borys DJ. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Subst Abus. 2013, 34:306-12. 10.1080\/08897077.2013.772083","journal-title":"Subst Abus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2013.07.004","article-title":"Case report and review of clenbuterol cardiac toxicity","volume":"8","author":"Barry AR","year":"2013","unstructured":"Barry AR, Graham MM. Case report and review of clenbuterol cardiac toxicity. J Cardiol Cases. 2013, 8:131-3. 10.1016\/j.jccase.2013.07.004","journal-title":"J Cardiol Cases"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.26502\/fccm.92920066","article-title":"Myocardial injury induced by the long acting beta2 adrenergic agonist clenbuterol","volume":"3","author":"Shafrir A","year":"2019","unstructured":"Shafrir A, W Leibowitz DW, Alcalai R, Elitzur Y, Muszkat M. Myocardial injury induced by the long acting beta2 adrenergic agonist clenbuterol. Cardiol Cardiovasc Med. 2019, 3:186-92. 10.26502\/fccm.92920066","journal-title":"Cardiol Cardiovasc Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.12890\/2020_001662","article-title":"Clenbuterol-induced myocarditis: a case report","volume":"7","author":"Moriarty N","year":"2020","unstructured":"Moriarty N, Attar N. Clenbuterol-induced myocarditis: a case report. Eur J Case Rep Intern Med. 2020, 7:001662. 10.12890\/2020_001662","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2015.12.086","article-title":"Clenbuterol causing non-ST-segment elevation myocardial infarction in a teenage female desiring to lose weight: case and brief literature review","volume":"34","author":"Quinley KE","year":"2016","unstructured":"Quinley KE, Chen HY, Yang HS, Lynch KL, Olson KR. Clenbuterol causing non-ST-segment elevation myocardial infarction in a teenage female desiring to lose weight: case and brief literature review. Am J Emerg Med. 2016, 34:1739.e5-7. 10.1016\/j.ajem.2015.12.086","journal-title":"Am J Emerg Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2018.01431","article-title":"Understanding the paths to appearance- and performance-enhancing drug use in bodybuilding","volume":"9","author":"Coquet R","year":"2018","unstructured":"Coquet R, Roussel P, Ohl F. Understanding the paths to appearance- and performance-enhancing drug use in bodybuilding. Front Psychol. 2018, 9:1431. 10.3389\/fpsyg.2018.01431","journal-title":"Front Psychol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.648467","article-title":"Enhancing the self: amateur bodybuilders making sense of experiences with appearance and performance-enhancing drugs","volume":"12","author":"Macho J","year":"2021","unstructured":"Macho J, Mudrak J, Slepicka P. Enhancing the self: amateur bodybuilders making sense of experiences with appearance and performance-enhancing drugs. Front Psychol. 2021, 12:648467. 10.3389\/fpsyg.2021.648467","journal-title":"Front Psychol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2016.1231173","article-title":"Outline of a typology of men\u2019s use of anabolic androgenic steroids in fitness and strength training environments*","volume":"24","author":"Christiansen AV","year":"2017","unstructured":"Christiansen AV, Vinther AS, Liokaftos D. Outline of a typology of men\u2019s use of anabolic androgenic steroids in fitness and strength training environments*. Drugs Educ Prev Policy. 2017, 24:295-305. 10.1080\/09687637.2016.1231173","journal-title":"Drugs Educ Prev Policy"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-3-7","article-title":"Psychological drivers in doping: the life-cycle model of performance enhancement","volume":"3","author":"Petr\u00f3czi A","year":"2008","unstructured":"Petr\u00f3czi A, Aidman E. Psychological drivers in doping: the life-cycle model of performance enhancement. Subst Abuse Treat Prev Policy. 2008, 3:7. 10.1186\/1747-597X-3-7","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00028.2007","article-title":"Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease","volume":"88","author":"Lynch GS","year":"2008","unstructured":"Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev. 2008, 88:729-67. 10.1152\/physrev.00028.2007","journal-title":"Physiol Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00139.2002","article-title":"Myotoxic effects of clenbuterol in the rat heart and soleus muscle","volume":"93","author":"Burniston JG","year":"2002","unstructured":"Burniston JG, Ng Y, Clark WA, Colyer J, Tan LB, Goldspink DF. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol (1985). 2002, 93:1824-32. 10.1152\/japplphysiol.00139.2002","journal-title":"J Appl Physiol (1985)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1981.tb00709.x","article-title":"Cardiopulmonary effects of clenbuterol in the horse","volume":"4","author":"Shapland JE","year":"1981","unstructured":"Shapland JE, Garner HE, Hatfield DG. Cardiopulmonary effects of clenbuterol in the horse. J Vet Pharmacol Ther. 1981, 4:43-50. 10.1111\/j.1365-2885.1981.tb00709.x","journal-title":"J Vet Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1988.254.6.E726","article-title":"Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist","volume":"254","author":"Zeman RJ","year":"1988","unstructured":"Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol. 1988, 254:E726-32. 10.1152\/ajpendo.1988.254.6.E726","journal-title":"Am J Physiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/BF01121878","article-title":"The effect of the anabolic agent, clenbuterol, on overloaded rat skeletal muscle","volume":"7","author":"Maltin CA","year":"1987","unstructured":"Maltin CA, Delday MI, Hay SM, Smith FG, Lobley GE, Reeds PJ. The effect of the anabolic agent, clenbuterol, on overloaded rat skeletal muscle. Biosci Rep. 1987, 7:143-9. 10.1007\/BF01121878","journal-title":"Biosci Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-0233(02)00178-8","article-title":"Chronic clenbuterol administration alters myosin heavy chain composition in standardbred mares","volume":"165","author":"Beekley MD","year":"2003","unstructured":"Beekley MD, Ideus JM, Brechue WF, Kearns CF, McKeever KH. Chronic clenbuterol administration alters myosin heavy chain composition in standardbred mares. Vet J. 2003, 165:234-9. 10.1016\/S1090-0233(02)00178-8","journal-title":"Vet J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/00005768-200212000-00018","article-title":"Clenbuterol diminishes aerobic performance in horses","volume":"34","author":"Kearns CF","year":"2002","unstructured":"Kearns CF, McKeever KH. Clenbuterol diminishes aerobic performance in horses. Med Sci Sports Exerc. 2002, 34:1976-85. 10.1097\/00005768-200212000-00018","journal-title":"Med Sci Sports Exerc"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1996.81.4.1610","article-title":"Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers","volume":"81","author":"Lynch GS","year":"1996","unstructured":"Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers. J Appl Physiol (1985). 1996, 81:1610-8. 10.1152\/jappl.1996.81.4.1610","journal-title":"J Appl Physiol (1985)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1023\/a:1027377731137","article-title":"Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses","volume":"24","author":"Plant DR","year":"2003","unstructured":"Plant DR, Kearns CF, McKeever KH, Lynch GS. Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses. J Muscle Res Cell Motil. 2003, 24:471-6. 10.1023\/a:1027377731137","journal-title":"J Muscle Res Cell Motil"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.2001.91.5.2064","article-title":"Chronic administration of therapeutic levels of clenbuterol acts as a repartitioning agent","volume":"91","author":"Kearns CF","year":"2001","unstructured":"Kearns CF, McKeever KH, Malinowski K, Struck MB, Abe T. Chronic administration of therapeutic levels of clenbuterol acts as a repartitioning agent. J Appl Physiol (1985). 2001, 91:2064-70. 10.1152\/jappl.2001.91.5.2064","journal-title":"J Appl Physiol (1985)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2005.05.002","article-title":"Adiponectin and leptin are related to fat mass in horses","volume":"172","author":"Kearns CF","year":"2006","unstructured":"Kearns CF, McKeever KH, Roegner V, Brady SM, Malinowski K. Adiponectin and leptin are related to fat mass in horses. Vet J. 2006, 172:460-5. 10.1016\/j.tvjl.2005.05.002","journal-title":"Vet J"},{"key":"ref39","unstructured":"Clenbuterol. what you need to know. (2020). Accessed: May 12, 2025: https:\/\/www.fda.gov\/animal-veterinary\/animal-drug-safety\/clenbuterol-what-you-need-know."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318295d766","article-title":"Pilot trial of clenbuterol in spinal and bulbar muscular atrophy","volume":"80","author":"Querin G","year":"2013","unstructured":"Querin G, D'Ascenzo C, Peterle E, et al.. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology. 2013, 80:2095-8. 10.1212\/WNL.0b013e318295d766","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161040-00004","article-title":"Managing cancer-related anorexia\/cachexia","volume":"61","author":"Mantovani G","year":"2001","unstructured":"Mantovani G, Macci\u00f2 A, Massa E, Madeddu C. Managing cancer-related anorexia\/cachexia. Drugs. 2001, 61:499-514. 10.2165\/00003495-200161040-00004","journal-title":"Drugs"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.12.001","article-title":"New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids","volume":"196","author":"Gorjao R","year":"2019","unstructured":"Gorjao R, Dos Santos CM, Serdan TD, et al.. New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids. Pharmacol Ther. 2019, 196:117-34. 10.1016\/j.pharmthera.2018.12.001","journal-title":"Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001842.pub2","article-title":"Adrenergic drugs for urinary incontinence in adults","volume":"2005","author":"Alhasso A","year":"2005","unstructured":"Alhasso A, Glazener CM, Pickard R, N'dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev. 2005, 2005:CD001842. 10.1002\/14651858.CD001842.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2174\/157488909789104794","article-title":"From antidepressant drugs to beta-mimetics: preclinical insights on potential new treatments for neuropathic pain","volume":"4","author":"Barrot M","year":"2009","unstructured":"Barrot M, Yalcin I, Choucair-Jaafar N, Benbouzid M, Freund-Mercier MJ. From antidepressant drugs to beta-mimetics: preclinical insights on potential new treatments for neuropathic pain. Recent Pat CNS Drug Discov. 2009, 4:182-9. 10.2174\/157488909789104794","journal-title":"Recent Pat CNS Drug Discov"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2025-264898","article-title":"Clenbuterol-induced myocardial infarction in a young bodybuilder","volume":"18","author":"Aggarwal A","year":"2025","unstructured":"Aggarwal A, Ansari AH, Isser HS, Kumar D. Clenbuterol-induced myocardial infarction in a young bodybuilder. BMJ Case Rep. 2025, 18:e264898. 10.1136\/bcr-2025-264898","journal-title":"BMJ Case Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2008.08.021","article-title":"Clenbuterol and the horse revisited","volume":"182","author":"Kearns CF","year":"2009","unstructured":"Kearns CF, McKeever KH. Clenbuterol and the horse revisited. Vet J. 2009, 182:384-91. 10.1016\/j.tvjl.2008.08.021","journal-title":"Vet J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2527\/1998.761195x","article-title":"Illegal use of beta-adrenergic agonists: European community","volume":"76","author":"Kuiper HA","year":"1998","unstructured":"Kuiper HA, Noordam MY, van Dooren-Flipsen MM, Schilt R, Roos AH. Illegal use of beta-adrenergic agonists: European community. J Anim Sci. 1998, 76:195-207. 10.2527\/1998.761195x","journal-title":"J Anim Sci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3920\/QAS2014.x006","article-title":"Food poisoning by clenbuterol in China","volume":"7","author":"Yan H","year":"2015","unstructured":"Yan H, Xu D, Meng H, Shi L, Li L. Food poisoning by clenbuterol in China. Qual Assur Saf Crops Foods. 2015, 7:27-35. 10.3920\/QAS2014.x006","journal-title":"Qual Assur Saf Crops Foods"},{"key":"ref49","unstructured":"Anabolic agents and meat contamination. (2016). https.\/\/www.usada.org\/spirit-of-sport\/clenbuterol-and-meat-contamination\/."},{"key":"ref50","unstructured":"Alberto Contador stripped of Tour title. (2012). Accessed. April 14, 2025: https:\/\/www.espn.in\/olympics\/cycling\/story\/_\/id\/7545798\/alberto-contador-stripped-2010-tour-de-france-title."},{"key":"ref51","unstructured":"List of doping cases in sport by substance. (2025). https.\/\/en.m.wikipedia.org\/w\/index.php?oldid=1281908593&title=List_of_doping_cases_in_sport_by_substance."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366381-clenbuterol-abuse-in-bodybuilding-and-athletics-unsupervised-use-psychological-motivations-and-health-consequences","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:50:24Z","timestamp":1748364624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366381-clenbuterol-abuse-in-bodybuilding-and-athletics-unsupervised-use-psychological-motivations-and-health-consequences"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.84904","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}